Phase I Study of a Combination of Doxil, VELCADE, and Gemcitabine in Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2013
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin liposomal; Gemcitabine
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 07 Aug 2009 Planned number of patients changed from 216 to 276 as reported by ClinicalTrials.gov.